The most talked about and market moving research calls around Wall Street are now in one place.
Here are today’s research calls that investors need to know, as compiled by The Fly
Top 5 Upgrades: – UBS upgraded Intuitive Surgical (ISRG) to Buy from Neutral with a price target of $500, down from $550, after a transfer in analyst coverage. The firm views the recent selloff in the shares as wrong. UBS’s work on automation suggests a “potentially dramatic acceleration” in penetration on procedures being brought to a point of faster and cheaper than laparoscopy today.
UBS also upgraded Stryker (SYK) to Buy from Neutral and Zimmer Biomet (ZBH) to Buy from Sell. – UBS upgraded Edwards Lifesciences (EW) to Buy from Neutral with a price target of $110, up from $90, after a transfer in analyst coverage. Edwards Lifesciences is entering a new growth phase driven by continued TAVR adoption, expansion into structural heart therapies, and a broader heart failure ecosystem, with shares undervaluing the durability of its innovation pipeline and potential for earnings growth and multiple expansion, the firm tells investors in a research note. – BofA upgraded Honeywell (HON) to Neutral from Underperform with a price target of $265, up from $205. Honeywell Technologies reported better-than-expected Q2 results and raised its 2026 guidance, with strong orders across all business segments improving confidence in second half growth, execution, and the potential for further earnings upgrades, the firm tells investors in a research note. – BNP Paribas upgraded Nutrien (NTR) to Outperform from Neutral with an $80 price target.